Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)

Cephalalgia

Volumn 17, Issue 18_suppl, 1997, Pages 21-27

  Rolan, P ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5HT1B 1D receptor agonists; Blood pressure; drug interactions; pharmacokinetics; zolmitriptan

Indexed keywords

DIHYDROERGOTAMINE; ERGOTAMINE; FLUOXETINE; METOCLOPRAMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PARACETAMOL; PIZOTIFEN; PLACEBO; PROPRANOLOL; SELEGILINE; ZOLMITRIPTAN; CAFERGOT; DIHYDROERGOTAMINE MESILATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MIXTURE; ORAL DRUG ADMINISTRATION;

ACETAMINOPHEN; ADOLESCENT; ADULT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ERGOTAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0030780405     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102497017S1804     Document Type: Article

References (24)

1. Martin G., Mechanism of action of zolmitriptan. Cephalalgia 1997; 17 Suppl 18: 4-14
2. Dixon R, Warrander A., The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl 18: 15-20
3. 1B/1D receptor agonists. Neurology 1997; 48 Suppl 3: S21-4
4. Seaber E, On N, Philips R, Churchus J, Posner J, Rolan P., The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthv male volunteers. Br J Clin Pharmacol 1996; 41: 141-7
5. Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan in combination with oral ergotamine in healthy volunteers. Cephalalgia 1997; 17: 639-46
6. Veronese L, Gillotin C, Marion-Gallois R, Weatherley BC, Thebault JJ, Guillaume M, Peck RW., Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan ("Zomig" 311C90) in healthy volunteers. Clin Drug Invest 1997; 14: 217-20
7. Seaber EJ, Gillotin C, Mohanlal R, Layton G, Posner J, Peck R., Lack of an interaction between pizotifen and the novel antimigraine compound zolmitriptan ("Zomig" 311C90). Clin Drug Invest 1997; 14: 221-5
8. Tfelt-Hansen P, Johnson ES., Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The Headaches. New York: Raven Press, 1993: 313-22
9. Dixon R, Meire HB, Leigh C, Posner J, Rolan PE., Evaluation of non-invasive methods to assess vasoconstriction in healthy volunteers using methoxamine as a probe drug. Cephalalgia 1996; 16: 507-17
10. Goadsby P, Olesen J., Diagnosis and management of migraine. Br Med J 1996; 312: 1279-83
11. Nimnio J, Heading RC, Tothill P, Prescott LF., Pharmacological modification of gastric emptying. Effects of propantheline and metoclopramide on paracetamol absorption. Br Med J 1973; 1: 587-9
12. 1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992; 6: 685-91
13. Usha Rani P, Naidu MUR, Ramesh Kumar Rao T, Mohan Das S, Shoba JC, Ravi Sekhar S, et al. Sumatriptan delays paracetamol absorption in migraine patients. Clin Drug Invest 1996; 11: 300-4
14. Bax ND, Tucker GT, Lennard MS, Woods HF., The impairment of lignocaine clearance by propranolol-major effects from enzyme inhibition. Br J Clin Pharmacol 1985; 19: 597-603
15. Conrad KA, Nyman DW., Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther 1980; 28: 463-7
16. Soons PA, De Boer A, Cohen AF, Breimer DD., The assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. Br J Clin Pharmacol 1991; 32: 697-704
17. Mylecharane EJ, Tfelt-Hansen P., Miscellaneous drugs. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993
18. Breslau N, Merikangas K, Bowden CL., Co-morbidity of migraine and major affective disorders. Neurology 1994; 44 Suppl 7: S17-22
19. Altamura AC, Moro AR, Percudani M., Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 210-14
20. Benfield P, Heel RC, Lewis SP., Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508
21. Rowland M, Tozer TN., Clinical pharmacokinetics: concepts and applications. 3rd edn. Baltimore: Lea and Febiger, 1995
22. 1B/1D agonist. Cephalalgia 1997; 17 Suppl 18: 41-52
23. Lloyd K., The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994; 34 Suppl 2: 40-3
24. Nielsen TH, Tfelt-Hansen P., Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 1989; 9 Suppl 9: 93-5